"Heparin, Low-Molecular-Weight" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
- Heparin, Low-Molecular-Weight
- Heparin, Low Molecular Weight
- Low Molecular Weight Heparin
- Low-Molecular-Weight Heparin
Below are MeSH descriptors whose meaning is more general than "Heparin, Low-Molecular-Weight".
Below are MeSH descriptors whose meaning is more specific than "Heparin, Low-Molecular-Weight".
This graph shows the total number of publications written about "Heparin, Low-Molecular-Weight" by people in this website by year, and whether "Heparin, Low-Molecular-Weight" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Heparin, Low-Molecular-Weight" by people in Profiles.
Parvizi J, DeMik DE, Hozack WJ, Dunbar MJ, Mont MA, Lachiewicz PA. Commentary on "Low Molecular Weight Heparin is Superior to Aspirin in the Prevention of Thromboembolic Disease, or is It? Response to an Editorial". J Arthroplasty. 2023 Apr; 38(4):e9.
Parvizi J, DeMik DE, Hozack WJ, Dunbar MJ, Mont MA, Lachiewicz PF. Low-Molecular-Weight Heparin Is Superior to Aspirin in the Prevention of Thromboembolic Disease: Or Is It? J Arthroplasty. 2023 Jan; 38(1):1-2.
Parvizi J, DeMik DE, Dunbar M, Hozack WJ, Mont MA, Lachiewicz PF. Low-Molecular-Weight Heparin Is Superior to Aspirin in the Prevention of Thromboembolic Disease: Or Is It? J Bone Joint Surg Am. 2022 Dec 07; 104(23):2045-2046.
Graif A, Kimbiris G, Grilli CJ, Agriantonis DJ, Putnam SG, Leung DA. Safety of Therapeutic Anticoagulation with Low-Molecular-Weight Heparin or Unfractionated Heparin Infusion during Catheter-Directed Thrombolysis for Acute Pulmonary Embolism. J Vasc Interv Radiol. 2020 Apr; 31(4):537-543.
Tan TL, Foltz C, Huang R, Chen AF, Higuera C, Siqueira M, Hansen EN, Sing DC, Parvizi J. Potent Anticoagulation Does Not Reduce Venous Thromboembolism in High-Risk Patients. J Bone Joint Surg Am. 2019 Apr 03; 101(7):589-599.
Porfidia A, Carnicelli A, Bonadia N, Pola R, Landolfi R. Controversies in venous thromboembolism: the unique case of isolated distal deep vein thrombosis. Intern Emerg Med. 2016 Sep; 11(6):775-9.
Vincentelli GM, Monti M, Pirro MR, Bertazzoni G, Pugliese FR, Ciammaichella M, Ruggieri MP, Landolfi R. Perception of Thromboembolism Risk: Differences between the Departments of Internal Medicine and Emergency Medicine. Keio J Med. 2016; 65(2):39-43.
Pick J, Berlin D, Horowitz J, Winokur R, Sista AK, Lichtman AD. Massive pulmonary embolism in pregnancy treated with catheter-directed tissue plasminogen activator. A A Case Rep. 2015 Apr 01; 4(7):91-4.
Khan MA, Brady CJ, Kaiser RS. Clinical management of proliferative vitreoretinopathy: an update. Retina. 2015 Feb; 35(2):165-75.
Baldwin AD, Robinson KG, Militar JL, Derby CD, Kiick KL, Akins RE. In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release. J Biomed Mater Res A. 2012 Aug; 100(8):2106-18.